Metsera Advances with Positive Phase IIa Results for Monthly GLP-1RA Dosing

Positive Phase IIa Results:
Metsera has announced positive topline results from its Phase IIa trial of MET-097i, a glucagon-like peptide-1 receptor agonist (GLP-1RA), showing a mean reduction in body weight of 11.3% over 12 weeks, adjusted for placebo, with some responses as high as 20%13.

Monthly Dosing Potential:
The trial supports the potential for monthly dosing, with the drug being well-tolerated and showing no weight loss plateau, indicating further weight loss potential with sustained use13.

Tolerability Profile:
MET-097i demonstrated a compelling tolerability profile, with mild gastrointestinal adverse events that were moderate and short-lived. Even at higher doses, the regimen was well-tolerated13.

Market Competition:
Metsera aims to compete with industry leaders like Novo Nordisk and Eli Lilly, whose products (Wegovy and Zepbound) require more frequent dosing1.

Future Plans:
Metsera is preparing for Phase III trials, set to begin this year, to further evaluate the efficacy and safety of MET-097i1.

Expert Endorsement:
John Buse, director of the University of North Carolina Diabetes Center, highlighted the potential of MET-097i as a foundational therapy for obesity and overweight due to its effectiveness, tolerability, and flexible dosing options1.

Sources:

1. https://www.clinicaltrialsarena.com/news/metsera-announces-positive-results-in-newest-phase-iia-glp-1ra/

3. https://www.biospace.com/drug-development/metsera-touts-powerful-weight-loss-results-again